Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: Forty-six patients completed 1 year of treatment. LS BMD increased by 2.66% (p=0.01), femoral neck (FN) by 4.81% (p=0.01), and any measured endpoint by 4.55% (p=0.0052). CONCLUSIONS:
|
Authors | Stephanie L Hines, Jeff A Sloan, Pamela J Atherton, Edith A Perez, Shaker R Dakhil, David B Johnson, Pavan S Reddy, Robert J Dalton, Bassam I Mattar, Charles L Loprinzi |
Journal | Breast (Edinburgh, Scotland)
(Breast)
Vol. 19
Issue 2
Pg. 92-6
(Apr 2010)
ISSN: 1532-3080 [Electronic] Netherlands |
PMID | 20079640
(Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, P.H.S.)
|
Copyright | Copyright 2009 Elsevier Ltd. All rights reserved. |
Chemical References |
- Aromatase Inhibitors
- Bone Density Conservation Agents
- Diphosphonates
- Imidazoles
- Nitriles
- Triazoles
- Zoledronic Acid
- Letrozole
|
Topics |
- Aromatase Inhibitors
(administration & dosage)
- Bone Density
- Bone Density Conservation Agents
(administration & dosage)
- Bone Diseases, Metabolic
(drug therapy)
- Breast Neoplasms
(drug therapy)
- Chemotherapy, Adjuvant
- Diphosphonates
(administration & dosage)
- Female
- Humans
- Imidazoles
(administration & dosage)
- Letrozole
- Nitriles
(administration & dosage)
- Osteoporosis
(drug therapy)
- Risk Factors
- Treatment Outcome
- Triazoles
(administration & dosage)
- Zoledronic Acid
|